These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23296837)

  • 21. Anti-Inflammatory and Neuroprotective Effects of Morin in an MPTP-Induced Parkinson's Disease Model.
    Hong DG; Lee S; Kim J; Yang S; Lee M; Ahn J; Lee H; Chang SC; Ha NC; Lee J
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson's disease mouse models.
    Lee YY; Park JS; Leem YH; Park JE; Kim DY; Choi YH; Park EM; Kang JL; Kim HS
    J Neuroinflammation; 2019 Dec; 16(1):246. PubMed ID: 31791357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease.
    Ren B; Zhang YX; Zhou HX; Sun FW; Zhang ZF; Wei Z; Zhang CY; Si DW
    J Neurol Sci; 2015 Jan; 348(1-2):142-52. PubMed ID: 25491263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.
    Chung YC; Kim SR; Park JY; Chung ES; Park KW; Won SY; Bok E; Jin M; Park ES; Yoon SH; Ko HW; Kim YS; Jin BK
    Neuropharmacology; 2011 May; 60(6):963-74. PubMed ID: 21288472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Papaverine inhibits α-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP/P mouse model of Parkinson's disease.
    Leem YH; Park JS; Park JE; Kim DY; Kang JL; Kim HS
    Biomed Pharmacother; 2020 Oct; 130():110576. PubMed ID: 32768884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-inflammatory and anti-apoptotic effects of (RS)-glucoraphanin bioactivated with myrosinase in murine sub-acute and acute MPTP-induced Parkinson's disease.
    Galuppo M; Iori R; De Nicola GR; Bramanti P; Mazzon E
    Bioorg Med Chem; 2013 Sep; 21(17):5532-47. PubMed ID: 23810671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible role of propofol's cyclooxygenase-inhibiting property in alleviating dopaminergic neuronal loss in the substantia nigra in an MPTP-induced murine model of Parkinson's disease.
    Kubo K; Inada T; Shingu K
    Brain Res; 2011 Apr; 1387():125-33. PubMed ID: 21376018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson's Disease.
    Siracusa R; Paterniti I; Cordaro M; Crupi R; Bruschetta G; Campolo M; Cuzzocrea S; Esposito E
    Mol Neurobiol; 2018 Mar; 55(3):2403-2419. PubMed ID: 28357809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
    Ishola IO; Oloyo AK; Olubodun-Obadun TG; Godswill OD; Omilabu SA; Adeyemi OO
    Metab Brain Dis; 2023 Feb; 38(2):557-571. PubMed ID: 36401682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease.
    Pariyar R; Bastola T; Lee DH; Seo J
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax.
    Youdim MB; Arraf Z
    Neuropharmacology; 2004 Jun; 46(8):1130-40. PubMed ID: 15111020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apelin-36 mediates neuroprotective effects by regulating oxidative stress, autophagy and apoptosis in MPTP-induced Parkinson's disease model mice.
    Zhu J; Gao W; Shan X; Wang C; Wang H; Shao Z; Dou S; Jiang Y; Wang C; Cheng B
    Brain Res; 2020 Jan; 1726():146493. PubMed ID: 31586624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse.
    Pierri M; Vaudano E; Sager T; Englund U
    Neuropharmacology; 2005 Mar; 48(4):517-24. PubMed ID: 15755479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.
    Dehmer T; Heneka MT; Sastre M; Dichgans J; Schulz JB
    J Neurochem; 2004 Jan; 88(2):494-501. PubMed ID: 14690537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total glucosides of paeony (TGP) extracted from Radix Paeoniae Alba exerts neuroprotective effects in MPTP-induced experimental parkinsonism by regulating the cAMP/PKA/CREB signaling pathway.
    Zheng M; Liu C; Fan Y; Shi D; Jian W
    J Ethnopharmacol; 2019 Dec; 245():112182. PubMed ID: 31445131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice.
    Costa T; Fernandez-Villalba E; Izura V; Lucas-Ochoa AM; Menezes-Filho NJ; Santana RC; de Oliveira MD; Araújo FM; Estrada C; Silva V; Costa SL; Herrero MT
    J Neuroimmune Pharmacol; 2021 Jun; 16(2):390-402. PubMed ID: 32564332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
    Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
    Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The neuroprotective effect of fisetin in the MPTP model of Parkinson's disease.
    Patel MY; Panchal HV; Ghribi O; Benzeroual KE
    J Parkinsons Dis; 2012; 2(4):287-302. PubMed ID: 23938259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models.
    Bao XQ; Kong XC; Qian C; Zhang D
    Neuroscience; 2012 Jan; 202():396-404. PubMed ID: 22138155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.